The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem
Honoraria - Bayer; Boehringer Ingelheim; Eisai; EMD Serono; Etubics; Exelixis; Genentech/Roche; Ipsen; Lexicon; Lilly; Merck; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Advanced Accelerator Applications; Celgene; Eisai; Eisai; Exelixis; Genentech/Roche; Ipsen; Lexicon; Merck; Novartis; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)
Patents, Royalties, Other Intellectual Property - Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY; PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES Publication number: 20170246136 Applicant: OliVentures, Inc. Inventors: Carlos María Peña Díaz, Guillermo Muñoz Fernández, Michael Morse; Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Assignee Duke University
 
Daniel M. Halperin
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Curium Pharma; Ipsen; Lexicon; Novartis
Research Funding - Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Incyte (Inst); Lexicon (Inst); Tarveda Therapeutics (Inst); Thermo Fisher Scientific (Inst)
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Stock and Other Ownership Interests - GeneCentric (I)
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Dekkun Corporation (Inst); Genentech/Roche (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
David S. Hsu
No Relationships to Disclose
 
Herbert Hurwitz
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Methods for treatment of Hand Foot Syndrome
 
Emily Bolch
No Relationships to Disclose
 
Dana Warren
No Relationships to Disclose
 
Sherri Haley
No Relationships to Disclose
 
Lisa John
No Relationships to Disclose
 
Ashley Moyer
Employment - Almac Group (I)
 
Christel N. Rushing
No Relationships to Disclose
 
Donna Niedzwiecki
No Relationships to Disclose